Monoclonal Antibodies for the Treatment of Patients With Multiple Myeloma

July 31, 2015
Ravi Vij, MD

Ravi Vij, MD, associate professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, discusses the monoclonal antibody daratumumab for the treatment of patients with heavily pretreated multiple myeloma.

Vij explains how patients with multiple myeloma are living much longer today than in the past. In fact, the median survival of patients is between eight and ten years. Unfortunately, the disease remains almost incurable, so new therapies and monoclonal antibodies are needed.

He believes daratumumab will greatly help patients because it is so well tolerated, and it will not negatively impact quality of life.

Ravi Vij, MD, associate professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, discusses the monoclonal antibody daratumumab for the treatment of patients with heavily pretreated multiple myeloma.